Keveyis: Fourth quarter revenue was $12.8 million and full-year revenue was $47.6 million. Management said Keveyis continued to outperform expectations, supported by an increase in the average number of patients on therapy, and noted the role of patient support for people living with primary periodic paralysis.Gvoke: Fourth quarter revenue was $24.6 million and full-year revenue was $94.1 million. Shannon said Gvoke posted 14% growth for the year, supported by broad access and alignment with treatment guide ...